Tennis-World No 1 Sinner cleared of wrongdoing after failed drug tests, ITIA says
Adds details, statements from Sinner and ATP
Aug 20 (Reuters) -World men's number one Jannik Sinner has been cleared of fault or negligence by an independent tribunal after failing two drug tests in March, the International Tennis Integrity Authority (ITIA) said on Tuesday.
The tribunal accepted Sinner's explanation that the anabolic agent clostebol entered his system from a member of his support team through massages and sports therapy, the ITIA said in a statement.
The team member had been applying an over-the-counter spray containing clostebol to their own skin to treat a small wound, the ITIA added.
"After each positive test, a provisional suspension was applied. On both occasions, Sinner successfully appealed the provisional suspension and so has been able to continue playing," the statement said.
The decision is subject to appeal by the World Anti-Doping Agency (WADA) and the Italian Anti-Doping Agency (NADO Italia), the statement added.
Sinner, who won the Cincinnati Open on Monday, said the independent tribunal had cleared him in April after he fully cooperated in the ITIA's investigation.
"I will now put this challenging and deeply unfortunate period behind me," he said in a statement, adding that the amount of clostebol found in his system was less than a billionth of a gram.
"I will continue to do everything I can to ensure I continue to comply with the ITIA's anti-doping programme and I have a team around me that are meticulous in their own compliance," he added.
The ATP said they were encouraged by the ruling.
"This has been a challenging matter for Jannik and his team, and underscores the need for players and their entourages to take utmost care in the use of products or treatments. Integrity is paramount in our sport," they said in a statement.
Australian Open champion Sinner will play in the U.S. Open later this month, with the main draw starting on Aug. 26.
Reporting by Chiranjit Ojha in Bengaluru; Editing by Hugh Lawson
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
